glycine has been researched along with Pancreatic Neoplasms in 31 studies
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcinoma." | 5.20 | A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. ( Aisner, DL; Bajaj, R; Baranda, JC; Bathini, V; Berlin, J; Boles, J; Cho, JK; Cohen, DJ; Cohen, SJ; Coveler, L; Cusnir, M; Fanta, P; Fehrenbacher, L; Gomes, CL; Granfortuna, J; Jimeno, A; Ma, WW; Maguire, R; Maniar, M; McRee, AJ; Menter, AR; Messersmith, WA; Nazemzadeh, R; O'Neil, BH; Olowokure, OO; Phillip, P; Radford, J; Rarick, M; Scott, AJ; Tejani, MA; Wilhelm, F, 2015) |
| " To address this problem, we have measured the synthetic rate of fibrinogen (perhaps the major acute phase protein) and plasma amino acid profiles in a group of patients with adenocarcinoma of the pancreas and an ongoing inflammatory response (serum C-reactive protein >10 mg/L in the absence of any other obvious infective or inflammatory cause)." | 3.70 | Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. ( Falconer, JS; Fearon, KC; McMillan, DC; Preston, T; Shenkin, A; Slater, C, 1998) |
| "Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18." | 2.77 | Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. ( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012) |
| "Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control." | 2.50 | Systematic reviews to ascertain the safety of diabetes medications. ( Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH, 2014) |
| "We exposed colorectal, breast and pancreatic cancer cell lines/organoids to radiation in vitro and in vivo in the presence and absence of exogenous serine and glycine." | 1.72 | Sensitisation of cancer cells to radiotherapy by serine and glycine starvation. ( Athineos, D; Blyth, K; Chalmers, AJ; Del Latto, M; Falcone, M; Gao, Y; Kierstead, M; Kim, JK; Maddocks, ODK; Newman, AC; Papalazarou, V; Romesser, PB; Sauvé, CG; Smith, JJ; Stevenson, K; Uribe, AH; Wu, C, 2022) |
| "Pancreatic cancer is one of the most malignant cancers." | 1.51 | Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. ( Fu, Y; Li, B; Liu, J; Luo, Y; Ma, X, 2019) |
| "As part of the Know Your Tumor project (Pancreatic Cancer Action Network), a 48-year-old female was diagnosed with metastatic PDA and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed." | 1.48 | Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. ( Bender, J; Brody, JR; Curtis, M; Fortuna, D; Heartwell, C; Jiang, W; Madhavan, S; Mason, K; Matrisian, LM; Peiper, SC; Petricoin, E; Pishvaian, MJ; Rahib, L; Varieur, K; Wang, ZX; Winter, JM; Yabar, CS; Yeo, CJ; Zarei, M, 2018) |
| "Six CDKN2A families had pancreatic cancer." | 1.31 | Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. ( Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA, 2000) |
| " Finally, glucagon-stimulated insulin secretion by RIN cells expressing the mutant receptor was decreased such that the dose-response curve was shifted to the right in comparison to that obtained with cells expressing the wild type receptor." | 1.29 | The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon. ( Abrahamsen, N; Froguel, P; Hager, J; Hansen, LH; Jelinek, L; Kindsvogel, W; Nishimura, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (16.13) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Falcone, M | 1 |
| Uribe, AH | 1 |
| Papalazarou, V | 1 |
| Newman, AC | 1 |
| Athineos, D | 2 |
| Stevenson, K | 1 |
| Sauvé, CG | 1 |
| Gao, Y | 1 |
| Kim, JK | 1 |
| Del Latto, M | 1 |
| Kierstead, M | 1 |
| Wu, C | 1 |
| Smith, JJ | 1 |
| Romesser, PB | 1 |
| Chalmers, AJ | 1 |
| Blyth, K | 2 |
| Maddocks, ODK | 2 |
| Banh, RS | 1 |
| Biancur, DE | 1 |
| Yamamoto, K | 1 |
| Sohn, ASW | 1 |
| Walters, B | 1 |
| Kuljanin, M | 1 |
| Gikandi, A | 1 |
| Wang, H | 1 |
| Mancias, JD | 1 |
| Schneider, RJ | 1 |
| Pacold, ME | 1 |
| Kimmelman, AC | 1 |
| Cheung, EC | 1 |
| Lee, P | 1 |
| Zhang, T | 1 |
| van den Broek, NJF | 1 |
| Mackay, GM | 1 |
| Labuschagne, CF | 1 |
| Gay, D | 1 |
| Kruiswijk, F | 1 |
| Blagih, J | 1 |
| Vincent, DF | 1 |
| Campbell, KJ | 1 |
| Ceteci, F | 1 |
| Sansom, OJ | 1 |
| Vousden, KH | 1 |
| Ma, X | 1 |
| Li, B | 1 |
| Liu, J | 1 |
| Fu, Y | 1 |
| Luo, Y | 1 |
| Fujimoto, TN | 1 |
| Colbert, LE | 1 |
| Huang, Y | 1 |
| Molkentine, JM | 1 |
| Deorukhkar, A | 1 |
| Baseler, L | 1 |
| Yu, M | 1 |
| Lin, D | 1 |
| Gupta, S | 1 |
| Cabeceiras, PK | 1 |
| Kingsley, CV | 1 |
| Tailor, RC | 1 |
| Sawakuchi, GO | 1 |
| Koay, EJ | 1 |
| Piwnica-Worms, H | 1 |
| Maitra, A | 1 |
| Taniguchi, CM | 1 |
| Gionfriddo, MR | 1 |
| Morey-Vargas, OL | 1 |
| Brito, JP | 1 |
| Leppin, AL | 1 |
| Murad, MH | 1 |
| Montori, VM | 1 |
| O'Neil, BH | 1 |
| Scott, AJ | 1 |
| Ma, WW | 2 |
| Cohen, SJ | 1 |
| Aisner, DL | 1 |
| Menter, AR | 1 |
| Tejani, MA | 1 |
| Cho, JK | 1 |
| Granfortuna, J | 1 |
| Coveler, L | 1 |
| Olowokure, OO | 1 |
| Baranda, JC | 1 |
| Cusnir, M | 1 |
| Phillip, P | 1 |
| Boles, J | 1 |
| Nazemzadeh, R | 1 |
| Rarick, M | 1 |
| Cohen, DJ | 1 |
| Radford, J | 1 |
| Fehrenbacher, L | 1 |
| Bajaj, R | 1 |
| Bathini, V | 1 |
| Fanta, P | 1 |
| Berlin, J | 1 |
| McRee, AJ | 1 |
| Maguire, R | 1 |
| Wilhelm, F | 2 |
| Maniar, M | 2 |
| Jimeno, A | 3 |
| Gomes, CL | 1 |
| Messersmith, WA | 2 |
| Athuluri-Divakar, SK | 1 |
| Vasquez-Del Carpio, R | 1 |
| Dutta, K | 1 |
| Baker, SJ | 1 |
| Cosenza, SC | 2 |
| Basu, I | 1 |
| Gupta, YK | 1 |
| Reddy, MV | 1 |
| Ueno, L | 1 |
| Hart, JR | 1 |
| Vogt, PK | 1 |
| Mulholland, D | 1 |
| Guha, C | 1 |
| Aggarwal, AK | 1 |
| Reddy, EP | 2 |
| Brody, JR | 1 |
| Yabar, CS | 1 |
| Zarei, M | 1 |
| Bender, J | 1 |
| Matrisian, LM | 1 |
| Rahib, L | 1 |
| Heartwell, C | 1 |
| Mason, K | 1 |
| Yeo, CJ | 1 |
| Peiper, SC | 1 |
| Jiang, W | 1 |
| Varieur, K | 1 |
| Madhavan, S | 1 |
| Petricoin, E | 1 |
| Fortuna, D | 1 |
| Curtis, M | 1 |
| Wang, ZX | 1 |
| Pishvaian, MJ | 1 |
| Winter, JM | 1 |
| Chan, A | 1 |
| Cusatis, G | 1 |
| Zhang, X | 1 |
| Wheelhouse, J | 1 |
| Solomon, A | 1 |
| Chan, F | 1 |
| Zhao, M | 1 |
| Ramana Reddy, MV | 1 |
| Rudek, MA | 1 |
| Kulesza, P | 1 |
| Donehower, RC | 1 |
| Hidalgo, M | 1 |
| Ray, KC | 1 |
| Bell, KM | 1 |
| Yan, J | 1 |
| Gu, G | 1 |
| Chung, CH | 1 |
| Washington, MK | 1 |
| Means, AL | 1 |
| Rachagani, S | 1 |
| Senapati, S | 1 |
| Chakraborty, S | 1 |
| Ponnusamy, MP | 1 |
| Kumar, S | 1 |
| Smith, LM | 1 |
| Jain, M | 1 |
| Batra, SK | 1 |
| Dy, GK | 1 |
| Weekes, CD | 1 |
| Whitworth, A | 1 |
| Ren, C | 1 |
| Eckhardt, SG | 1 |
| Adjei, AA | 1 |
| Avan, A | 1 |
| Pacetti, P | 1 |
| Reni, M | 1 |
| Milella, M | 1 |
| Vasile, E | 1 |
| Mambrini, A | 1 |
| Vaccaro, V | 1 |
| Caponi, S | 1 |
| Cereda, S | 1 |
| Peters, GJ | 1 |
| Cantore, M | 1 |
| Giovannetti, E | 1 |
| Giger, U | 1 |
| Büchler, M | 1 |
| Farhadi, J | 1 |
| Berger, D | 1 |
| Hüsler, J | 1 |
| Schneider, H | 1 |
| Krähenbühl, S | 1 |
| Krähenbühl, L | 1 |
| Manzoni, MF | 1 |
| Franchi, GM | 1 |
| Sartorio, SM | 1 |
| Di Rosa, E | 1 |
| Cappelletti, C | 1 |
| Piani, C | 1 |
| Cattaneo, C | 1 |
| Ferrari, M | 1 |
| Bosi, E | 1 |
| Carrera, P | 1 |
| Ollila, S | 1 |
| Dermadi Bebek, D | 1 |
| Greenblatt, M | 1 |
| Nyström, M | 1 |
| Allen, L | 1 |
| Meck, R | 1 |
| Yunis, A | 1 |
| Finkelstein, SD | 1 |
| Przygodzki, R | 1 |
| Pricolo, VE | 1 |
| Sayegh, R | 1 |
| Bakker, A | 1 |
| Swalsky, PA | 1 |
| Keller, G | 1 |
| Hansen, LH | 1 |
| Abrahamsen, N | 1 |
| Hager, J | 1 |
| Jelinek, L | 1 |
| Kindsvogel, W | 1 |
| Froguel, P | 1 |
| Nishimura, E | 1 |
| Kowalski-Chauvel, A | 1 |
| Pradayrol, L | 1 |
| Vaysse, N | 1 |
| Seva, C | 1 |
| Kamohara, H | 1 |
| Sakamoto, K | 1 |
| Mita, S | 1 |
| An, XY | 1 |
| Ogawa, M | 1 |
| Preston, T | 1 |
| Slater, C | 1 |
| McMillan, DC | 1 |
| Falconer, JS | 1 |
| Shenkin, A | 1 |
| Fearon, KC | 1 |
| Aoki, Y | 1 |
| Kawa, S | 1 |
| Karasawa, Y | 1 |
| Horiuchi, A | 1 |
| Kiyosawa, K | 1 |
| Goldstein, AM | 1 |
| Struewing, JP | 1 |
| Chidambaram, A | 1 |
| Fraser, MC | 1 |
| Tucker, MA | 1 |
| Bugaj, JE | 1 |
| Erion, JL | 1 |
| Johnson, MA | 1 |
| Schmidt, MA | 1 |
| Srinivasan, A | 1 |
| Hino, M | 1 |
| Nagatsu, T | 1 |
| Kakumu, S | 1 |
| Okuyama, S | 1 |
| Yoshii, Y | 1 |
| Nagatsu, I | 1 |
| Nagata, Y | 1 |
| Abe, M | 1 |
| Motoshima, K | 1 |
| Nakayama, E | 1 |
| Shiku, H | 1 |
| Azuma, T | 1 |
| Inokuchi, H | 1 |
| Kawai, K | 1 |
| Fujimoto, S | 1 |
| Nakajima, M | 1 |
| Taggart, RT | 1 |
| Walsh, JH | 1 |
| Kierulf, P | 1 |
| Godal, HC | 1 |
| Brunner, G | 1 |
| Sommer, J | 1 |
| Kattermann, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer[NCT01360853] | Phase 3 | 160 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent[NCT02562443] | Phase 3 | 372 participants (Actual) | Interventional | 2015-12-02 | Terminated (stopped due to Top line analysis indicated that the study had failed to achieve its primary endpoint.) | ||
| Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine[NCT01241500] | Phase 3 | 299 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase II Single-arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-resistant Ovarian Cancer[NCT00856791] | Phase 2 | 1 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 5-day Continuous Intravenous Dosing Of ON 01910.Na Administered Every 2 Weeks in Patients With Intermediate-1, Intermediate-2, or High Risk Myelodysplastic Syndrome (MDS)[NCT00867061] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2009-03-31 | Withdrawn (stopped due to Mutual decision by site and sponsor because of difficulty recruiting Patients.) | ||
| Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors[NCT01125891] | Phase 1 | 39 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors[NCT00861328] | Phase 1 | 18 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors[NCT00861783] | Phase 1 | 16 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy[NCT02655081] | Phase 2 | 48 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of adverse events and their severity rating will be classified according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version 3.0. (NCT00856791)
Timeframe: 6 months
| Intervention | Adverse event (Number) |
|---|---|
| ON 01910.Na | 9 |
Progression-free survival, defined as the number of days from the first day of study drug dosing to the day of documented disease progression or death, as assessed using RECIST (Response Evaluation Criteria in Solid Tumors) guidelines according to Therasse P, Arbuck SF, Eisenhauer EA, et al. (2000) J Natl Cancer Inst. 92:205-216. Progressive disease is defined as at least a 20% increase in the sum of the longest diameter (LD)of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00856791)
Timeframe: 6 months
| Intervention | day (Number) |
|---|---|
| ON 01910.Na | 54 |
1 review available for glycine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractur | 2014 |
3 trials available for glycine and Pancreatic Neoplasms
| Article | Year |
|---|---|
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ce | 2012 |
Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery-a randomized controlled pilot study.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Enteral | 2007 |
27 other studies available for glycine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Sensitisation of cancer cells to radiotherapy by serine and glycine starvation.
Topics: Amino Acids; Animals; Antioxidants; Glycine; Mice; Pancreatic Neoplasms; Serine | 2022 |
Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Animals; Axons; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Prolifera | 2020 |
Modulating the therapeutic response of tumours to dietary serine and glycine starvation.
Topics: Animals; Antioxidants; Biguanides; Cell Line, Tumor; Diet; Disease Models, Animal; Female; Food Depr | 2017 |
Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
Topics: Animals; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Eukaryotic Initiation Factor | 2019 |
Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer.
Topics: Animals; Apoptosis; Female; Glycine; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; M | 2019 |
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Topics: Amino Acid Sequence; Animals; Cell Cycle Proteins; Cell Transformation, Neoplastic; Crystallography, | 2016 |
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Topics: Amino Acid Sequence; Animals; Cell Cycle Proteins; Cell Transformation, Neoplastic; Crystallography, | 2016 |
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Topics: Amino Acid Sequence; Animals; Cell Cycle Proteins; Cell Transformation, Neoplastic; Crystallography, | 2016 |
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Topics: Amino Acid Sequence; Animals; Cell Cycle Proteins; Cell Transformation, Neoplastic; Crystallography, | 2016 |
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Pancreatic Ductal; DNA Mutational Analysis; Drug Resistanc | 2018 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; | 2009 |
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.
Topics: Amino Acid Substitution; Animals; Aspartic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Ce | 2011 |
Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Aspartic Acid; Cadherins; Down-Regulation; Gene Ex | 2011 |
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; | 2013 |
A novel MEN1 gene mutation.
Topics: Arginine; Carcinoma, Papillary; Female; Germ-Line Mutation; Glycine; Humans; Middle Aged; Multiple E | 2008 |
Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification.
Topics: Asparagine; Aspartic Acid; Biliary Tract Neoplasms; Blotting, Western; Colorectal Neoplasms, Heredit | 2008 |
The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501).
Topics: Antibiotics, Antineoplastic; Cells, Cultured; gamma-Glutamyltransferase; Glycine; Half-Life; Humans; | 1980 |
K-ras-2 topographic genotyping of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Alanine; Arginine; Aspartic Acid; Codon; Cysteine; DNA, Neoplasm; Exons; Forecasting | 1994 |
The Gly40Ser mutation in the human glucagon receptor gene associated with NIDDM results in a receptor with reduced sensitivity to glucagon.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Cyclic AMP; Diabetes Mellitus, Type 2; Exons; G | 1996 |
Tyrosine phosphorylation of insulin receptor substrate-1 and activation of the PI-3-kinase pathway by glycine-extended gastrin precursors.
Topics: Androstadienes; Animals; Enzyme Activation; Enzyme Inhibitors; Gastrins; Glycine; Insulin Receptor S | 1997 |
Neutrophil elastase inhibitor (ONO-5046.Na) suppresses the proliferation, motility and chemotaxis of a pancreatic carcinoma cell line, Capan-1.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Movement; Chemotaxi | 1997 |
Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response.
Topics: Acute-Phase Reaction; Adenocarcinoma; Adult; Aged; Amino Acids; C-Reactive Protein; Cachexia; Fastin | 1998 |
Anti-proliferative effects of unmodified antisense oligodeoxynucleotides targeted against c-raf mRNA: use of poly (lysine/serine) copolymers or cationic lipopolyamines.
Topics: Cations; Cell Division; Drug Carriers; Glycine; Humans; Oligonucleotides, Antisense; Pancreatic Neop | 1998 |
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; G | 2000 |
Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats.
Topics: Animals; Glycine; Male; Pancreatic Neoplasms; Radiochemistry; Radiopharmaceuticals; Rats; Rats, Inbr | 2001 |
Glycylprolyl beta-naphthylamidase activity in human serum.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferas | 1975 |
Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese.
Topics: Adult; Aged; Asian People; Aspartic Acid; Codon; Female; Genes, ras; Glycine; Humans; Japan; Male; M | 1990 |
Carboxyl terminal glycine extended progastrin (gastrin-G) in human gastric mucosa and gastrinomas.
Topics: Duodenal Neoplasms; Gastric Mucosa; Gastrinoma; Gastrins; Glycine; Humans; Pancreatic Neoplasms; Pro | 1989 |
Fibrinaemia and multiple thrombi in pancreatic carcinoma. A case studied with quantitative N-terminal analysis.
Topics: Alanine; Blood Coagulation; Blood Coagulation Tests; Disseminated Intravascular Coagulation; Fibrin; | 1972 |
[On the behavior of the so-called leucine aminopeptidase (LAP) in the serum during the application of various substrates].
Topics: Adolescent; Adult; Aged; Animals; Aspartate Aminotransferases; Biliary Tract Diseases; Cholestasis; | 1968 |